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Availability, prices, and affordability of
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middle-income country – the case of
Mexico
Daniela Moye-Holz1* , Margaret Ewen2 , Anahi Dreser3 , Sergio Bautista-Arredondo3 , Rene Soria-Saucedo4 ,
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Abstract
Background: More alternatives have become available for the diagnosis and treatment of cancer in low- and
middle-income countries. Because of increasing demands, governments are now facing a problem of limited
affordability and availability of essential cancer medicines. Yet, precise information about the access to these
medicines is limited, and the methodology is not very well developed. We assessed the availability and affordability
of essential cancer medicines in Mexico, and compared their prices against those in other countries of the region.
Methods: We surveyed 21 public hospitals and 19 private pharmacies in 8 states of Mexico. Data were collected on
the availability and prices of 49 essential cancer medicines. Prices were compared against those in Chile, Peru, Brazil,
Colombia and PAHO’s Strategic Fund.
Results: Of the various medicines, mean availability in public and private sector outlets was 61.2 and 67.5%,
respectively. In the public sector, medicines covered by the public health insurance “People’s Health Insurance”
were more available. Only seven (public sector) and five (private sector) out of the 49 medicines were considered
affordable. Public sector procurement prices were 41% lower than in other countries of the region.
Conclusions: The availability of essential cancer medicines, in the public and private sector, falls below World
Health Organization’s 80% target. The affordability remains suboptimal as well. A national health insurance scheme
could serve as a mechanism to improve access to cancer medicines in the public sector. Comprehensive pricing
policies are warranted to improve the affordability of cancer medicines in the private sector.
Keywords: Availability, Affordability, Prices, Essential cancer medicines, Mexico
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: danymoyeholz@gmail.com
1Department of Community and Occupational Medicine, University Medical
Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ
Groningen, The Netherlands
Full list of author information is available at the end of the article
Moye-Holz et al. BMC Health Services Research          (2020) 20:424 
https://doi.org/10.1186/s12913-020-05167-9
Background
Comprehensive cancer care requires a number of inter-
ventions, from specialized diagnostics to various
treatments including: surgery, radiotherapy, and chemo-
therapy [1, 2]. Low-cost and effective medicines to treat
several cancers exist in generic form [3]. However, the
prices of many cancer medicines (both generic and origi-
nators) make them unaffordable for governments and
patients, and contribute to their in health facilities in
many low- and middle-income countries (LMIC) [4].
Unavailable and unaffordable essential cancer medicines
may lead to substandard and/or interrupted treatment
regimens, worse health outcomes, and lower chances of
survival [2]. Therefore, equitable access to affordable
essential medicines is a crucial component of compre-
hensive cancer care [3, 5–7].
In absolute terms, cancer has become a leading cause of
death and disability around the globe. Yet, many patients
in LMIC remain untreated [2, 3, 8, 9], and access to cancer
care, including medicines, is becoming a priority. Describ-
ing the current access to cancer medicines and under-
standing the barriers that hinder their accessibility [10] are
key components to develop responsive national policies,
and to measure their impact. In general, comparable infor-
mation about access to cancer medicines is limited world-
wide [10, 11]. Direct assessment of the availability and
affordability of essential cancer medicines has rarely been
conducted in LMICs [11], except in Tanzania [12] and
Pakistan [13]. Most studies have been limited to infectious
diseases and medicines to treat non-communicable
diseases (NCDs) other than cancer [14–17].
In Mexico, cancer accounts for nearly 13% of deaths
[18–20]. Cancer care in Mexico is available in the public
and private sectors. In the public sector, social health in-
surance institutions provide comprehensive health ser-
vices (including cancer treatment) to employees in the
formal sector. People who are ineligible for social health
insurance can affiliate to the People’s Health Insurance
(Seguro Popular de Salud - SPS) – a federal government
insurance scheme that reimburses health facilities (usually
Ministry of Health (MoH) facilities) according to a catalog
of services [21, 22]. This population can also receive
coverage for high-cost services (e.g. all pediatric cancers
and eight types of cancers in adults) through the Fund
against Catastrophic Expenditures (FPGC) [2, 23]. SPS
patients receive healthcare and medicines at the point of
service with no additional cost. For those diseases not cov-
ered by SPS, patients might pay out-of-pocket for some
services and medicines according to their level of income.
The private sector consists of private pharmacies and
health facilities where patients pay additional insurance
contributions or out-of-pocket [21]. While several studies
have investigated insurance coverage for breast, cervical
and children cancer care in the public sector [23–25],
there is scant research on the availability and affordability
of cancer medicines.
The purpose of this study was to assess and compare
the availability and affordability of essential cancer medi-
cines in the public and private sectors in Mexico. We
also compared consumer procurement and consumer
prices in the two sectors against those in four other
middle-income countries in the region (Brazil, Colombia,
Chile and Peru).
Methods
The standardized World Health Organization/Health
Action International (WHO/HAI) methodology [26] that
measures medicine prices, availability and affordability
was adapted to study essential medicines for cancer, col-
lecting data from a sample of public hospitals and pri-
vate pharmacies across the country.
Sample
We selected 49 cancer medicines (each strength and
dose-form specific) from the national formulary. Accord-
ing to the national clinical guidelines, the SPS protocols
and the National Institute of Cancerology’s (INCAN)
guidelines, these medicines are required for the treat-
ment of breast cancer, colorectal cancer, leukemia and
renal cancer. Of these, the SPS reimburses 40 medicines
(for more information on the medicines of study see
Additional file 1).
Data were collected in Mexican states where cancer
care is provided. A total of 26 specialized and tertiary
hospitals in the public sector were selected from eight of
32 states of the country, with differing levels of
marginalization [27, 28], Organization for Economic Co-
operation and Development (OECD) health well-being
levels [29], and with at least one MoH hospital specialized
in cancer care (Table 1). In this way, our sample captured
the variability and characteristics of the health system. We
surveyed all MoH hospitals providing cancer care in the
selected states except in Chihuahua, Oaxaca and Veracruz.
We did not survey five hospitals in these three states due
to logistical issues and hospital’s refusal to participate.
Cancer medicines are not always continuously stocked
in private pharmacies. Instead, pharmacies that dispense
these medicines usually do so from a fixed inventory list,
with next-day delivery. We selected 1 to 3 pharmacies that
market specialty medicines (e.g. cancer medicines) in each
of the eight states, resulting in a total of 19 pharmacies.
Data collection
The survey was conducted from March to June 2017.
From the public sector hospital pharmacies, we recorded
whether the medicine was in stock at the time of the visit
(yes/no), and the price paid by the hospital and by the
patient (if applicable). We did not distinguish between
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originator brands or generics, because the Mexican public
sector regularly procures generic versions of multisource
medicines and only provides originator (patented) medi-
cines when no generics are available.
In the private sector pharmacies, we recorded whether
the medicine was included in the pharmacy’s inventory
and could be ordered for next-day delivery (yes/no), the
price paid by patients of the lowest-priced generic avail-
able and the price of the patented medicines.
Data analysis
We conducted the data analysis using the WHO/HAI
methodology workbook [26] as described in the follow-
ing sections.
Availability
We assessed availability in each sector by calculating the
percentage of facilities where each medicine was avail-
able, and the mean across a collection of medicines. In
the public sector, we also compared availability per dis-
ease, since breast cancer and colorectal cancer are cov-
ered by SPS for adults and children, while leukemia and
renal cancer are covered for children only.
Affordability
We assessed affordability from the patient’s perspective
when paying out-of-pocket. For each medicine, we com-
pared the defined daily dose values [30] and the median
unit price with the minimum daily wage in 2017 [26,
31]. Based on affordability assessments by Khatib et. Al
[32] and Sarwar et al. [13], we considered a medicine as
affordable if 20% or less of the daily wage was needed to
pay for 1 day of medicine [13, 32]. In public hospitals,
affordability was only assessed in the three hospitals
where patients pay out-of-pocket for cancer medicines.
We were not able to include data from the other hospi-
tals, as these reported that patients did not pay out-of-
pocket for their medicines or only paid a co-payment
(for all healthcare services) according to their level of in-
come when they do not have SPS coverage.
Prices and international price comparison
The WHO/HAI methodology expresses prices as a ratio
(Median Price Ratio (MPR)) to international reference
prices, which are the median supplier prices reported by
Management Sciences for Health (MSH) [33]. As MSH
reported prices for a limited number of the study medi-
cines, prices from publicly accessible websites of com-
parable countries in the region were also used as
external benchmark, namely Brazil, Colombia, Chile (re-
cently considered a high-income country) and Peru [34–
37]. To calculate MPRs, MSH international reference
prices, the Pan-American Health Organization (PAHO)
Strategic Fund procurement prices and 2017 median
public sector procurement prices in the comparator
countries were compared with Mexican public procure-
ment prices. For patient prices, comparisons were made
with median patient prices of patented and lowest priced
generic medicines in the comparator countries.
Results
Availability and affordability of medicines in the public
and private sectors
Table 2 shows the availability and affordability of cancer
medicines in the public hospitals and private pharmacies
we surveyed. In the public sector, the overall mean avail-
ability was 61.2%, with 70.2% availability of the SPS med-
icines. Mean availability of medicines was: for breast
cancer 81.8%, for leukemia 69.2%, for colorectal cancer
62.9%, and renal cancer 57.3%. Overall availability in the
private sector was 67.4%. Generic medicines (60.6%)
were more available than patented medicines (54.0%).
The availability of patented medicines was below 50% in
the public and private sectors for most medicines except
bevacizumab 400mg, L-asparaginase, mercaptopurine,
rituximab 100 mg and 500 mg, and trastuzumab.
In the public sector, the median affordability (n = 49
medicines) was 1.45 days’ wages required to purchase
1 day’s supply. Seven medicine products were considered
affordable, that is, 1 day of medicine supply costs 20% or
less of the daily wage: etoposide, fluorouracil, letrozole,
methotrexate (2.5 mg tablet (tab), 500 mg injectable (inj)
Table 1 Characteristics of selected states and number of facilities surveyed
State Level of Marginalization OECDa Health well-being indicator No. Public Hospitals surveyed No. Private Pharmacies surveyed
Campeche High Low 1 1
Oaxaca High Low 2 2
Veracruz High Low 3 2
Chihuahua Medium Low 2 2
Guanajuato Medium Medium 3 3
Yucatan Medium Medium 2 3
Jalisco Low High 4 3
Mexico City Low High 4 3
aOECD Organization for Economic Co-operation and Development
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Table 2 Availability and affordability of 49 selected cancer medicines in public hospitals and private pharmacies
Availability Affordabilitya
No. Medicine Public Sector (n = 21) Private Sector (n = 19) Public Sector (n = 21) Private Sectorb (n = 19)
1 Anastrozole 1 mg tab 76.19% 89.47% 0.24 0.59
2 Bevacizumab 100mg inj 42.86% 73.68% 30.12 57.68
3 Bevacizumab 400mg inj 66.67% 68.42% 29.42 51.99
4 Capecitabine 500 mg tab 76.19% 78.95% 1.88 5.50
5 Carboplatin 150 mg inj 85.71% 68.42% 0.44 0.83
6 Cetuximab 5mg/ml inj 38.10% 36.84% 35.74 62.88
7 Cyclophosphamide 200mg inj 80.95% 84.21% 0.48 0.67
8 Cyclophosphamide 500mg inj 95.24% 73.68% 0.53 0.64
9 Cytarabine 500mg inj 95.24% 84.21%
10 Dasatinib 50 mg tab 4.76% 31.58% 17.20 33.95
11 Daunorubicin 20mg inj 66.67% 63.16%
12 Docetaxel 20 mg/1ml inj 66.67% 78.95% 5.26 8.00
13 Docetaxel 80 mg/4ml inj 71.43% 84.21% 3.78 6.59
14 Doxorubicin 10mg inj 85.71% 73.68% 0.61 1.09
15 Doxorubicin 50mg inj 85.71% 84.21% 0.45 0.57
16 Epirubicin 10 mg/5ml inj 42.86% 63.16% 3.00
17 Epirubicin 50 mg/25ml inj 61.90% 84.21% 0.57 1.86
18 Etoposide 20mg/ml inj 95.24% 78.95% 0.16 0.33
19 Everolimus 10mg tab 14.29% 42.11% 21.26 30.17
20 Everolimus 5 mg tab 9.52% 42.11% 30.17
21 Exemestane 25 mg tab 85.71% 78.95% 1.02 0.73
22 Fluorouracil 250 mg inj 80.95% 52.63% 0.10 0.16
23 Folinic Acid 50mg/4ml inj 95.24% 63.16%
24 Folinic Acid 15mg tab 42.86% 57.89%
25 Gemcitabine 1 g inj 76.19% 78.95% 1.09 4.86
26 Ifosfamide 1 g inj 85.71% 73.68% 3.15 5.50
27 Imatinib 100 mg tab 33.33% 63.16% 3.58 17.59
28 Imatinib 400 mg tab 38.10% 47.37% 3.43 18.63
29 Irinotecan 20 mg/ml inj 76.19% 68.42% 3.18 7.25
30 L-Asparaginase 10,000 IU inj 76.19% 84.21% 13,15 17.03
31 Letrozole 2.5 mg tab 66.67% 84.21% 0.20 0.44
32 Mercaptopurine 50mg tab 52.38% 84.21% 1.45 2.38
33 Methotrexate 2.5 mg tab 71.43% 84.21% 0.02 0.07
34 Methotrexate 500 mg inj 80.95% 78.95% 0.02 0.02
35 Methotrexate 50 mg inj 95.24% 68.42% 0.06 0.11
36 Nilotinib 200 mg tab 23.81% 36.84% 21.72
37 Oxaliplatin 100 mg/20 ml inj 61.90% 84.21% 0.89 2.36
38 Oxaliplatin 50 mg/10ml inj 57.14% 73.68% 1.25 2.40
39 Paclitaxel 6 mg/ml inj 80.95% 78.95% 0.45 1.63
40 Panitimumab 20 mg/ml inj 28.57% 42.11% 31.72 58.93
41 Pazopanib 200mg tab 9.52% 26.32% 14.89
42 Pazopanib 400mg tab 4.76% 52.63% 8.49 14.89
43 Rituximab 100mg/10 ml inj 61.90% 68.42% 6.65 30.97
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and 50mg inj) and tamoxifen. In the private sector, five
medicine products were considered affordable: fluoro-
uracil, methotrexate 500 mg inj and 50 mg inj, tamoxi-
fen, and methotrexate 2.5 mg tab. The median price of
overall medicines in the private sector was 5.50 days’
wages needed to buy 1 day of one medicine’s supply.
The median affordability of patented medicines was
30.17 days’ wages needed to buy 1 day of one medicine’s
supply. For the generic medicines, it was 0.78 days’
wages.
Procurement and patient prices
Table 3 shows median public sector procurement prices
and median patient prices in the private sector, both in
local currency (Mexican peso (Mex$)) and as ratios to
median prices in the four comparator countries and
international reference prices. In the public sector, the
overall median procurement price in Mexico was 0.59
times (41% below) the median comparator country price
and 0.80 times (20% below) the MSH international refer-
ence prices. However, the prices of a few individual
medicines were over twice the median comparator coun-
try price, e.g. MPR of anastrozole (2.12x), docetaxel 80
mg (5.56x) and 20 mg inj (3.40x). The prices of docetaxel
20 mg/ml (12.42x) and 80 mg/ml (12.08x), folinic acid
50mg/ml (3.88x) and irinotecan (6.16x) were over three
times the MSH international reference prices. For pa-
tient prices in the private sector, overall medicines had
median MPRs of 0.65 (35% below the reference prices).
Cancer medicines ranged from an MPR of 0.13 for oxali-
platin 50 mg inj to 2.48 for docetaxel 80 mg inj. Most
medicine prices were 2 to 6 times higher in the other
Latin American (LATAM) countries compared to
Mexico. On the other hand, six medicines were cheaper
in Peru. Only the price of docetaxel was consistently
higher in Mexico (Fig. 1).
Discussion
In Mexico, the overall availability of cancer essential
medicines in the public sector was slightly lower than in
the private sector. In general, prices in Mexico were
lower than international reference prices and lower than
other LATAM countries. Only few medicines were con-
sidered affordable in both the public and private sectors;
affordability of medicines in the public sector (14% of
medicines) was slightly better than in the private sector
(10% of medicines).
Availability of cancer medicines
The average availability of cancer medicines was lower in
the public sector (61.2%) than in the private sector
(67.45%), with high variability across individual medicines.
The availability of SPS medicines was slightly higher
(70.2%), especially for those for breast cancer and
leukemia. Greater availability reflects an increased govern-
ment investment in these two types of cancer treatments.
Access to colorectal cancer medicines was lower than
breast cancer and leukemia medicines; barriers to access
essential medicines for colorectal cancer have been re-
ported [22], despite the fact that colorectal cancer is cov-
ered by SPS. Renal cancer medicines for adult patients
had the lowest availability of all, likely because they are
not covered by SPS and therefore deprioritized [38, 39].
Overall, the availability of cancer medicines falls below
the World Health Organization’s (WHO) target of 80%
for essential medicines to treat major NCDs (which in-
cludes cancer) [40–42]. Thus, mechanisms to improve the
availability of cancer medicines in Mexico are warranted.
Table 2 Availability and affordability of 49 selected cancer medicines in public hospitals and private pharmacies (Continued)
Availability Affordabilitya
44 Rituximab 500mg/50 ml inj 71.43% 68.42% 4.65 30.96
45 Sorafenib 200mg tab 19.05% 57.89% 19.59 31.13
46 Sunitinib 12.5 mg tab 14.29% 47.37% 11.89 25.10
47 Tamoxifen 20 mg tab 90.48% 78.95% 0.02 0.06
48 Trastuzumab 440mg inj 71.40% 57.89% 13.77 23.63
49 Vincristine 1 mg inj 85.71% 78.95% 0.35 0.45
Mean availability/Median affordability 61.20% 67.45% 1.45 5.50
Mean availability/Median affordability:
Breast cancer medicines 74.8% 78.1% 0.57 1.36
Leukemia medicines 59.3% 66.4% 3.50 17.72
Colorectal cancer medicines 55.6% 58.3% 2.53 6.37
Renal cancer medicines 52.0% 61.9% 1.09 17.72
tab tablet, inj injectable, mg milligrams, ml milliliters, IU international unit, n number of facilities surveyed and included in the analysis
aAffordability is expressed as number of days needed to purchase 1 day of treatment based in minimum daily wage
bAffordability in the private sector: we present only the affordability of the lowest priced generic medicines. For medicines with no generic alternatives, we
present the affordability of the patented/originator medicine
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Table 3 Median public sector procurement prices and median patient prices, in local currency and as price ratios to median prices
in the four-comparator countries
Public Sector Procurement Price Private Sector Patient Pricea
No. Medicine Name Median Price (Mex$) MPR (LATAMc) MPR (MSH) Median Price (Mex$) MPR (LATAMc)
1 Anastrozole 1 mg tab 24.29 2.12 2.35 47.36 1.27
2 Bevacizumab 100mg inj 53.58 0.58 102.59 0.82
3 Bevacizumab 400mg inj 48.67 0.66 92.48 0.84
4 Capecitabine 500mg tab 22.07 0.59 0.67 73.33 0.89
5 Carboplatin 150 mg inj 1.27 0.31 0.65 2.67 0.21
6 Cetuximab 5 mg/ml inj 40.81 0.61 77.43 1.01
7 Cyclophosphamide 200 mg inj 0.15 0.41 0.36 0.21 0.35
8 Cyclophosphamide 500 mg inj 0.14 0.37 0.45 0.20 0.42
9 Cytarabine 500mg inj 0.30 1.08 1.66 0.60 0.58
10 Dasatinib 50 mg tab 573.78 0.57 1132.27 1.46
11 Daunorubicin 20 mg inj 5.90 0.25 0.31 12.99 0.31
12 Docetaxel 20 mg/1ml inj 62.93 3.40 12.42 99.53 0.54
13 Docetaxel 80 mg/4ml inj 51.83 5.56 12.08 82.00 2.48
14 Doxorubicin 10 mg inj 7.45 1.23 1.79 17.53 0.42
15 Doxorubicin 50 mg inj 3.92 0.86 1.38 9.20 0.49
16 Epirubicin 10mg/5ml inj 12.84 0.36 1.20 34.35 0.59
17 Epirubicin 50mg/25 ml inj 6.20 0.41 0.73 21.28 0.38
18 Etoposide 20 mg/ml inj 0.49 0.64 1.30 1.06 2.01
19 Everolimus 10 mg tab 1702.00 0.83 2414.97 0.65
20 Everolimus 5 mg tab 425.50 0.44 1207.48 0.65
21 Exemestane 25mg tab 69.18 1.08 1.69 58.50 0.66
22 Fluorouracil 250 mg inj 0.08 0.49 0.38 0.13 0.63
23 Folinic Acid 50 mg/4ml inj 3.56 0.76 3.88 4.60 1.14
24 Folinic Acid 15 mg tab 15.84 0.71 0.62 23.33 0.80
25 Gemcitabine 1 g inj 0.44 0.32 0.89 1.95 0.37
26 Ifosfamide 1 g inj 0.27 0.75 1.30 0.63 0.83
27 Imatinib 100 mg tab 57.32 0.54 4.22 281.58 0.52
28 Imatinib 400 mg tab 219.48 0.77 0.44 1192.74 0.66
29 Irinotecan 20 mg/ml inj 6.97 1.20 6.16 19.34 0.35
30 L-Asparaginase 10,000 IU inj 0.11 0.49 1.06 0.14 0.92
31 Letrozole 2.5 mg tab 2.62 0.04 0.28 35.00 1.03
32 Mercaptopurine 50 mg tab 33.24 0.59 0.76 54.48 1.25
33 Methotrexate 2.5 mg tab 1.20 0.36 0.39 5.81 1.73
34 Methotrexate 500 mg inj 0.45 1.13 1.35 0.79 0.61
35 Methotrexate 50 mg inj 1.22 0.59 0.59 3.44 1.05
36 Nilotinib 200 mg tab 279.07 0.56 11.92 579.59 0.84
37 Oxaliplatin 100 mg/20ml inj 6.36 0.78 0.43 17.15 0.18
38 Oxaliplatin 50mg/10 ml inj 8.52 1.11 0.75 17.45 0.13
39 Paclitaxel 6 mg/ml inj 2.78 0.76 8.72 0.58
40 Panitimumab 20 mg/ml inj 76.99 0.84 157.23 1.18
41 Pazopanib 200mg tab 170.44 0.56 297.90 0.59
42 Pazopanib 400mg tab 339.86 0.57 595.85 0.45
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Low availability in the private sector could be explained by
the fact that specialized medicines are marketed in se-
lected pharmacy chains only. Therefore, patients have a
limited choice of pharmacies, restricted to some states
and mostly in urban areas.
The availability of cancer medicines in Mexico’s public
sector is higher than other LMIC countries from which
data were available. For example, studies in Tanzania
and Pakistan [12, 13] reported 50% availability of cancer
medicines in the public sector. In Pakistan, the availabil-
ity of cancer medicines in the private sector was higher
than in the public sector, which is a common trend in
LMIC [13]. However, private pharmacies in Pakistan
focus more on stocking originator brand cancer medi-
cines, while in Mexico private pharmacies have a better
availability of generic cancer medicines [13].
Affordability of cancer medicines
Most cancer medicines are unaffordable for patients, in
the private and in three public hospitals where patients
paid for cancer medicines. Based on our own definition,
only 7 out of 49 cancer medicines were affordable [13, 32].
In addition, most cancer treatment regimens require more
than one medicine, making the treatment as a whole even
less affordable, often leading to catastrophic expenditures
and poverty [6, 43, 44]. The studies from Tanzania and
Pakistan also reported that cancer medicines required
more than one working day to pay for 1 day of treatment,
therefore considered unaffordable to most patients [12,
13]. These results, including Mexico, confirm the LMIC’s
general picture of unaffordability of essential cancer medi-
cines. Therefore, more aggressive pricing policies are
needed to disrupt this ongoing problem.
We also found that 18 out of 21 of the public hospitals
we surveyed reported no additional charges for patients
without SPS coverage, as a mechanism to guarantee
access to treatment without incurring in health expend-
iture. For those hospitals that do charge uninsured pa-
tients for treatment, these patients must make out-of-
pocket payments for (mostly) unaffordable medicines
and/or turn to charity organizations [23, 45].
Procurement prices and international price comparison
We found that, in general, prices of cancer medicines in
the public sector in Mexico were lower than other
LATAM countries and international reference prices.
The Mexican government has contained procurement
prices better in the public sector than other countries in
the region, through pooled procurement, price negotia-
tions and using reference pricing for SPS medicines [46–
49]. For SPS medicines, most public procurement prices
were under the SPS reference prices [47, 50], and overall
about 20% lower than (MSH) international reference
prices. Still, additional efforts are needed to further re-
duce and monitor prices; in particular for those that are
more than twice the reference prices (e.g. docetaxel).
Overall, medicine prices in Mexico’s private sector
were lower than retail prices in the regional countries.
Yet, current prices, especially for patented medicines, re-
main unaffordable, warranting the development of com-
prehensive price regulations schemes, which has not
been properly introduced in the country yet [46, 51].
High prices of patented cancer medicines seem common
in the region, as other LATAM countries, such as
Argentina, Chile, Uruguay, Paraguay and Brazil have re-
ported unaffordable prices as well [52]. Such high prices
in the private sector usually lead to catastrophic expend-
iture, in particular for low-income patients who were
unable to get their medicines in the public sector [6].
Besides wider national health insurance coverage for
public sector medicines, additional pricing policies are
Table 3 Median public sector procurement prices and median patient prices, in local currency and as price ratios to median prices
in the four-comparator countries (Continued)
Public Sector Procurement Price Private Sector Patient Pricea
No. Medicine Name Median Price (Mex$) MPR (LATAMc) MPR (MSH) Median Price (Mex$) MPR (LATAMc)
43 Rituximab 100 mg/10ml inj 13.09 0.45 0.49 77.46 0.85
44 Rituximab 500 mg/50ml inj 10.82 0.21 0.31 77.44 1.26
45 Sorafenib 200mg tab 404.04 0.73 622.82 0.67
46 Sunitinib 12.5 mg tab 326.01 0.43 717.58 0.53
47 Tamoxifen 20mg tab 1.46 0.68 0.66 4.90 0.41
48 Trastuzumab 440mg inj 49.29 0.68 94.56 0.97
49 Vincristine 1 mg inj 53.66 0.36 0.84 101.00 0.53
Median 12.84 0.59 0.80 41.18 0.65
OB originator brand, LPG lowest price generic, tab tablet, inj injectable, mg milligrams, ml milliliters, IU international unit, n number of facilities surveyed and
included in the analysis, LATAMc Latin American countries, MPR median price ratio, Mex$ mexican peso, MSH management sciences for health
aMedian prices and MPR in the private sector: we present only the median prices and the MPR of the lowest priced generic medicines. For medicines with no
generic alternatives, we present the median prices and the MPR of the patented/originator medicine
Moye-Holz et al. BMC Health Services Research          (2020) 20:424 Page 7 of 11
necessary to improve access to more affordable cancer
medicines in the private sector.
Strengths and limitations
To our knowledge, this is the first study on the availability,
prices, and affordability of cancer medicines using an
adapted form of the WHO/HAI methodology. This study
collected data from a representative sample of public hos-
pitals and private pharmacies in eight states. Future
research should also consider assessing the availability, af-
fordability, and prices of cancer medicines in other insur-
ance schemes (social health insurance institutions) and
other geographic regions of Mexico.
This study has some limitations. At the time of data
collection, some medicines were reported as “just be-
came out-of-stock”. Thus, our availability data may
underestimate the actual availability of cancer medicines
on a regular basis [26]. At one surveyed hospital, some
Fig. 1 Price differences between public procurement prices in Mexico (=1) and other LATAM countries and PAHO’s Strategic Fund
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medicine prices were restricted, as this information per-
tained to the state’s MoH database. In addition, our cal-
culations of patient affordability account for single
medicine for 1 day of treatment, which may underesti-
mate the affordability of the treatment as a whole. Fur-
thermore, our affordability assessment in the public
sector is limited to the only 3 hospitals that reported pa-
tient prices for cancer medicines, which may understate
our results on medicine’s affordability in the public sec-
tor. However, the current results show that medicines
are still unaffordable to patients that receive care at
those institutions and pay out of pocket for medicines
without coverage.
We only surveyed pharmacies in the private sector be-
cause we did not obtain approval from private hospitals
to conduct our research. Private hospitals providing can-
cer care provide chemotherapy at their facilities and care
for approximately 19% of cancer cases [53]. Hence, our
results do not fully represent the availability, prices, and
affordability of cancer medicines in the private sector as
a whole. However, the private sector hospitals and
clinics represent approximately 2% [54] of the pharma-
ceutical market. Thus, omitting these data is not likely
to have resulted in significant bias in our observations.
Additional research is necessary to describe the availabil-
ity and affordability of cancer medicines in this private
subsector.
Practical implications
Medicines in the public sector covered by SPS were the
most available, especially for breast cancer and leukemia.
These results reflect the additional investment by the
government to improve health care access to priority
diseases. We recommend periodically revising and up-
dating the SPS’s protocols for “resource appropriate
strategies” [2] that guarantee the best level of care with
the most efficacious and cost-effective medicines, includ-
ing innovative medicines. We also recommend the ex-
pansion of SPS coverage to improve access to treatment
to all types of cancer.
Overall, the Mexican government has kept prices of
cancer medicines in the public sector below prices from
other LATAM countries. Yet, most medicines remain
unaffordable for patients – particularly for innovative
medicines under patent. A comprehensive assessment of
the government’s budget allocations and the complete
calculation of costs of cancer care (i.e. pharmaceutical
and non-pharmaceutical) are required.
The high prices and low affordability of cancer medi-
cines in the private sector reflect a lack of pricing policies
and pharmaceutical market regulation. Price monitoring,
prices transparency for single-source products, and com-
pulsory licensing when all other measured fail to yield af-
fordable medicines, should be implemented to increase
affordability for payers (patients and the health system).
Mexico should also consider the full range of pricing pol-
icies [55] for medicines in the public and private sectors
to assure the provision of affordable medicines for all
patients.
Further research is needed to assess the affordability of
medicines and comprehensive cancer treatments, both
from the patient’s and the health system’s perspective.
Continuous monitoring of prices and availability of can-
cer medicines is necessary to monitor their impact on
health expenditure and access to cancer care.
Conclusions
The availability of cancer medicines in public hospitals
and private pharmacies in Mexico need to improve in
order to reach WHO’s target of 80% availability. The
SPS should be used as a public mechanism to ensure ap-
propriate and timely access to cancer medicines. Al-
though prices in the public sector were lower than in
other countries of the region, most cancer medicines
continue to be unaffordable to patients in Mexico. Com-
prehensive pricing policies are needed to improve the af-
fordability of cancer medicines in the public and private
sectors.
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1186/s12913-020-05167-9.
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Characteristics of selected medicines of study following inclusion criteria.
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